ADC Therapeutics
ADCT
59 hedge funds and large institutions have $90.9M invested in ADC Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
7.31% more ownership
Funds ownership: 50.49% → 57.8% (+7.3%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
2% less funds holding
Funds holding: 60 → 59 (-1)
39% less capital invested
Capital invested by funds: $149M → $90.9M (-$58.2M)
65% less call options, than puts
Call options by funds: $8K | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$22M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$10.3M |
| 3 |
SCM
Sio Capital Management
New York
|
+$7.97M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$6.08M |
| 5 |
PA
Perceptive Advisors
New York
|
+$5.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.8M |
| 3 |
Millennium Management
New York
|
-$5.93M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.71M |
| 5 |
Walleye Capital
New York
|
-$1.97M |
ADCT Hedge Fund Activity: Q1 2023 in Review
59 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q1 2023, worth a combined $90.9M — down 39% from $149M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ADCT and 17 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 20 added.
The largest buyer was Redmile Group, adding an estimated $22M. The largest seller was Fidelity Investments, cutting an estimated $17M.
- 59 institutional investors held ADC Therapeutics (ADCT) as of Q1 2023, down from 60 in Q4 2022.
- Funds reported $90.9M of ADC Therapeutics stock for Q1 2023, down 39% quarter-over-quarter.
- 17 funds opened new ADC Therapeutics positions in Q1 2023 and 18 closed out, a net change of -1 holder.
- The largest ADC Therapeutics buyer in Q1 2023 was Redmile Group, an estimated $22M added.
- The largest ADC Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $17M sold.
Based on aggregated 13F filings for Q1 2023.